Two Hot Stocks Under Limelight: Alamos Gold Inc. (NYSE:AGI), Clovis Oncology, Inc. (NASDAQ:CLVS)

Alamos Gold Inc. (NYSE:AGI)

Alamos Gold Inc. (NYSE:AGI) closed at $6.24 on the last trading session with an decrease of -1.58%, whereas, it previously closed at $6.34. The company has a market capitalization of $2.43 Billion. The company traded shares of 2.88 Million on the trading day while its three month average volume stands at 3 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Alamos Gold Inc. (NYSE:AGI) produced diluted EPS of -0.07. The EPS estimate for next year as estimated by analysts is at 0.22 while EPS for next quarter is estimated at 0.06. Earnings per Share growth for this year is reported at 650, while the analysts estimated the EPS growth for next year at 0.22% and Earnings growth for next 5 years stands at 0% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -28.13%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Alamos Gold Inc. (NYSE:AGI) is at 0 while the forward p/e is at 28.36. The P/S or Price to Sales ratio of Alamos Gold Inc. (NYSE:AGI) stands at 3.84 and Price to Book or P/B for the most recent quarter stands at 0.92. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Alamos Gold Inc. (NYSE:AGI) are reported at 0 and 0 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Alamos Gold Inc. (NYSE:AGI) stands at 0, 0 and 0 respectively

The trailing twelve month Revenue of Alamos Gold Inc. (NYSE:AGI) is reported at 634 Million with income of 0. The outstanding shares of Alamos Gold Inc. (NYSE:AGI) are 389.94 Million. The institutional Ownership of the shares of 65.56 stands at 0.80%, this figure is increased 0 in the last six months. The insider ownership for the shares of Alamos Gold Inc. (NYSE:AGI) is ticked at 0.27%, the figure is rose 0% in the last six months.

Some other important financial aspects to be discussed here for Alamos Gold Inc. (NYSE:AGI) is the Mean Target Price estimated by the analysts which stands at 9.01. The 52 week high of Alamos Gold Inc. (NYSE:AGI) is placed at 7.78 and 52 week low is standing at 2.90.

Performance wise the shares of Alamos Gold Inc. (NYSE:AGI) fell down -3.55% for the week, it also fell -10.47% for the monthly performance, while for the quarter it went down 11.03%. The shares increase 17.96% for the half year and flew up for the Year-To-Date performance. The shares of Alamos Gold Inc. (NYSE:AGI) grew 39.29% for the yearly performance.

Clovis Oncology, Inc. (NASDAQ:CLVS)

Clovis Oncology, Inc. (NASDAQ:CLVS) closed at $5.14 on the last trading session with an decrease of -3.75%, whereas, it previously closed at $5.34. The company has a market capitalization of $296.53 Million. The company traded shares of 5.61 Million on the trading day while its three month average volume stands at 3.3 Million.

Now to discuss some of the Earning per Share estimates and growth estimates, shares of Clovis Oncology, Inc. (NASDAQ:CLVS) produced diluted EPS of -7.49. The EPS estimate for next year as estimated by analysts is at -5.83 while EPS for next quarter is estimated at -1.85. Earnings per Share growth for this year is reported at -80.5, while the analysts estimated the EPS growth for next year at -5.83% and Earnings growth for next 5 years stands at 33.7% as estimated by the analysts. While Annual EPS Growth rate for past five years as reported by the company is at -19.1%.

Some important ratios are also vital to discuss the performance of the company and its shares. The P/E or Price to Earnings ratio of Clovis Oncology, Inc. (NASDAQ:CLVS) is at 0 while the forward p/e is at 0. The P/S or Price to Sales ratio of Clovis Oncology, Inc. (NASDAQ:CLVS) stands at 2.49 and Price to Book or P/B for the most recent quarter stands at 0. The Price to Free Cash Flow ratio or P/FCF is reported at 0. The quick ratio and the current ratio of Clovis Oncology, Inc. (NASDAQ:CLVS) are reported at 3.3 and 3.6 respectively. The Return on Assets ROA, Return On Earnings ROE and ROI Return On Investment for Clovis Oncology, Inc. (NASDAQ:CLVS) stands at -49.1, -372.7 and -50.1 respectively

The trailing twelve month Revenue of Clovis Oncology, Inc. (NASDAQ:CLVS) is reported at 119.2 Million with income of -396000000. The outstanding shares of Clovis Oncology, Inc. (NASDAQ:CLVS) are 57.69 Million. The institutional Ownership of the shares of 0 stands at 0.80%, this figure is increased 3.95 in the last six months. The insider ownership for the shares of Clovis Oncology, Inc. (NASDAQ:CLVS) is ticked at 2.5%, the figure is rose 7.27% in the last six months.

Some other important financial aspects to be discussed here for Clovis Oncology, Inc. (NASDAQ:CLVS) is the Mean Target Price estimated by the analysts which stands at 21.4. The 52 week high of Clovis Oncology, Inc. (NASDAQ:CLVS) is placed at 34.63 and 52 week low is standing at 4.98.

Performance wise the shares of Clovis Oncology, Inc. (NASDAQ:CLVS) fell down -14.76% for the week, it also fell -13.61% for the monthly performance, while for the quarter it went up -65.2%. The shares decrease -79.68% for the half year and plummeted for the Year-To-Date performance. The shares of Clovis Oncology, Inc. (NASDAQ:CLVS) shrinked -84.05% for the yearly performance.